Enterprise Therapeutics has closed an oversubscribed GBP29m (USD41m) Series B round co-led by Versant Ventures and Novartis Venture Fund, the biopharmaceutical company disclosed on Thursday.
Also involved in the funding was new investor Forbion, founding investor Epidarex Capital, and existing investor IP Group.
The funding will go towards the company's drug discovery pipeline of muco-regulatory therapies and progressing them into clinical development. Enterprise Therapeutics is focused on providing new treatment options for cystic fibrosis, chronic obstructive pulmonary disease (COPD), and severe asthma.
The muco-regulatory therapies are being developed to treat patients with respiratory diseases of high unmet medical need, where mucus obstruction reduces lung function, resulting in breathing difficulties and recurrent lung infections. The therapies target the ion channels TMEM16A and ENaC with the aim of increasing hydration and clearing mucus.
Enterprise Therapeutics has also identified novel targets and compounds that reduce mucus production, which is thought to complement mucus hydration therapies.
cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial
First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant
Insmed completes adult patient enrolment in brensocatib pivotal ASPEN study
Aluna Raises USD 15.3m in Series B Funding
CF Foundation Invests Up to USD 15m in ReCode Therapeutics for Development of mRNA Therapy
Markels Named to Arcturus Therapeutics Board of Directors
SpliSense commences first-in-human, Phase 1/2 clinical trial of SPL84 to treat cystic fibrosis
Arcturus Forges Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
Vanda Pharmaceuticals VPO-227 granted US FDA Orphan Drug Designation for the treatment of cholera